Personalized Cystic Fibrosis Therapy

The Division of Pulmonary and Sleep Medicine received new National Institutes of Health funding (P30) to test and implement personalized therapies in cystic fibrosis (CF). The funding supports a wide spectrum of senior and junior investigators who have focused their research on CF. The new research program takes advantage of new innovative technologies developed at Cincinnati Children’s. These technologies include lung, pancreas and intestines on a chip. It could now be possible to test response to Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulators in vitro. The lead investigators are Drs. Anjaparavanda Naren, PhD; JP Clancy, MD; and Jeffery Whitsett, MD.